Capricor TherapeuticsCAPR
CAPR
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 17
133% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 15
87% more capital invested
Capital invested by funds: $128M [Q3] → $239M (+$111M) [Q4]
44% more funds holding
Funds holding: 75 [Q3] → 108 (+33) [Q4]
25% more call options, than puts
Call options by funds: $33.1M | Put options by funds: $26.6M
12.21% more ownership
Funds ownership: 25.89% [Q3] → 38.1% (+12.21%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
225%
upside
Avg. target
$54
480%
upside
High target
$77
735%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Kristen Kluska 25% 1-year accuracy 27 / 106 met price target | 225%upside $30 | Overweight Reiterated | 20 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 17% 1-year accuracy 56 / 327 met price target | 735%upside $77 | Buy Reiterated | 20 Mar 2025 |
Financial journalist opinion
Based on 8 articles about CAPR published over the past 30 days
Neutral
Seeking Alpha
2 weeks ago
Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marban - Chief Executive Officer Conference Call Participants Edward Tenthoff - Piper Sandler Leland Gershell - Oppenheimer Joseph Pantginis - H.C.
Negative
Zacks Investment Research
2 weeks ago
Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.02 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a corporate update.
Neutral
GlobeNewsWire
2 weeks ago
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
--Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the 2025 Muscular Dystrophy Association (MDA) Conference--
Neutral
PRNewsWire
3 weeks ago
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
PARAMUS, N.J. , March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd.
Neutral
GlobeNewsWire
3 weeks ago
Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that Capricor management will participate in one-on-one investor meetings and provide a corporate update at Leerink's Global Healthcare Conference 2025, taking place March 10-12, 2025 in Miami, Florida.
Positive
Seeking Alpha
4 weeks ago
Capricor: Further Value Unlocked With Priority Review Of Deramiocel
Capricor Therapeutics, Inc.'s Deramiocel received FDA Priority Review with a PDUFA target date of August 31, 2025, for the treatment of patients with DMD Cardiomyopathy. Deramiocel could become the first FDA-approved drug for DMD cardiomyopathy patients, targeting a group of patients with no currently available treatment options. The StealthX exosome platform from the company shows promise, potentially enhancing drug delivery and gene expression inhibition for DMD patients by possibly providing 2.5X greater exon skipping.
Positive
Benzinga
4 weeks ago
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition
On Tuesday, the FDA accepted for review Capricor Therapeutics Inc's CAPR Biologics License Application for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy.
Positive
Seeking Alpha
1 month ago
Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data
Capricor Therapeutics has filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD cardiomyopathy, with strong FDA recognition. Deramiocel's efficacy was demonstrated in the HOPE-2 trials, with significant improvements in PUL 1.2 scores and positive long-term benefits in PUL 2.0 and LVEF measures. Financially, Capricor is well-positioned with a strong cash runway, strategic partnerships, and projected significant revenue from deramiocel sales by 2030.
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade
The consensus price target hints at a 208.1% upside potential for Capricor (CAPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Charts implemented using Lightweight Charts™